Watson seeks to market generic Jalyn
PARSIPPANY, N.J. — Watson Pharmaceuticals is hoping to be the first to market a generic version of a GlaxoSmithKline drug for men with an enlarged prostate, Watson said.
Watson announced that it filed a regulatory approval application to market a generic version of GSK’s Jalyn (dutasteride and tamsulosin hydrochloride) capsules, a treatment for symptomatic benign prostatic hyperplasia in men with enlarged prostates.
Watson’s filing contained a Paragraph IV certification, a legal assertion that patents covering Jalyn are invalid, unenforceable or won’t be infringed. In response, under the Hatch-Waxman Act of 1984, GSK filed suit against Watson to try and prevent it from commercializing the drug before the expiration of U.S. Patent No. 5,565,467, which will occur in November 2015.
Jalyn had sales of more than $30 million during the 12-month period ended in May, according to IMS Health.
Prasco to sell authorized generic of Ponstel
CINCINNATI — Prasco Labs has contracted to sell an authorized generic version of a painkiller made by Shionogi, Prasco said Monday.
Under the agreement between the two companies, Prasco will market and distribute an authorized generic version of Ponstel (mefenamic acid) capsules in the 250-mg strength.
“With the introduction of the authorized generic of Shionogi’s Ponstel, Prasco continues to be the preferred partner for established brand companies to transcend their brands with our authorized generics,” Prasco CEO E. Thomas Arington said. “We are pleased to have established this relationship with Shionogi Inc., a company that has been providing innovative medicines essential to people’s health.”
Authorized generics are branded drugs sold under their generic names, usually as part of an agreement by a branded drug maker and a third-party company.
VoicePort partners with Unwired Nation to extend platforms to mobile apps
ROCHESTER, N.Y. — Speech-recognition software developer VoicePort and mobile-applications-as-a-service company Unwired Nation have entered an agreement to port the former’s customer service software to smartphones and tablets, the companies said.
Rochester, N.Y.-based VoicePort and Austin, Texas-based Unwired Nation will use VoicePort’s Kinita and PharmaPhonetics platform to create mobile apps. VoicePort’s software uses advanced speech recognition self-service technology to automate interactions for the pharmacy and pharmaceutical industries.
PharmaPhonetics delivers automated, personalized and intelligent interactive communications that speak directly to patients on behalf of the pharmacy and can be used for such services as prescription pickup, refill reminders and health awareness messaging.
“We know our clients need to communicate with their customers — patients — simply, clearly and via whatever smartphone or tablet that customer is using,” VoicePort president and CEO Christopher Mann said. “Unwired Nation helps us deliver this to our pharmacy and pharmaceutical clients today, and we see opportunities to leverage this mobile technology in the near future, augmented and accelerated by our own integration expertise, in our other businesses verticals that include media, publishing and enterprise solutions.”